Biophytis // Marktkap €3 M -Kurs 0.21
Seite 1 von 1 Neuester Beitrag: 25.04.21 02:04 | ||||
| Eröffnet am: | 06.12.19 11:30 | von: Biolover | Anzahl Beiträge: | 10 |
| Neuester Beitrag: | 25.04.21 02:04 | von: Stefanieqtuo. | Leser gesamt: | 3.658 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Biophytis (ALBPS) Marktkap €3 M--Cashbestand €5,2 M --Phase 2b Studie für die Sarkopenie Studie läuft ,eine Krankheit für das es bisher KEIN zugelassenes Medikament gibt und Start Phase 1/2 in DMD in kürze =MULTIBAGGER Potential
Kursziel €4 laut diesem analystenhaus hier
https://www.biophytis.com/wp-content/uploads/2019/...EPORT-030419.pdf
Kursziel €4 laut diesem analystenhaus hier
https://www.biophytis.com/wp-content/uploads/2019/...EPORT-030419.pdf
IND approval sollte spätestens in 10 tagen da sein ,
Biophytis Files IND Application with FDA for Sarconeos (BIO101) to Support Planned MYODA Clinical Program in Patients with DMD...November 15, 2019
https://www.biophytis.com/wp-content/uploads/2019/...-PR-EN-Final.pdf
Pipeline
https://www.biophytis.com/en/pipeline/
Biophytis Files IND Application with FDA for Sarconeos (BIO101) to Support Planned MYODA Clinical Program in Patients with DMD...November 15, 2019
https://www.biophytis.com/wp-content/uploads/2019/...-PR-EN-Final.pdf
Pipeline
https://www.biophytis.com/en/pipeline/
Biophytis presented updates from the ongoing SARA-OBS and SARA-INT studies in sarcopenia, as well as preclinical studies in DMD, at multiple scientific conferences. Presented results covered the baseline characteristics of sarcopenic population and the efficiency of recruitment protocol in SARA-OBS study. Additionally, the preclinical results showed encouraging activity of Sarconeos in DMD, supporting the initiation of clinical studies in this indication. We updated our financial model to reflect pipeline updates and 2018 financial results. Due to the anticipated delays in Macuneos program, we lower our TP to €4.4 (vs €6.0). Reiterate BUY.
Biophytis’ drug-development platform utilizes natural substances that have favorable pharmacologic profile and promising biological activity. Company’s is focusing its efforts on the lead asset, Sarconeos, which is a MAS receptor activator and could potentially preserve muscle function in muscle-wasting diseases. Sarconeos is being evaluated in the Phase 2b SARA-INT study in sarcopenia, with a potential readout in 2020. Additionally, Biophytis is planning to initiate MYODA clinical program in DMD in 2020 (subject to regulatory approval). When Sarconeos is successfully out-licensed,Biophytis is planning to pursue the development of its second asset, Macuneos, in the dry form of age-related maculardegeneration (AMD).
Biophytis’ drug-development platform utilizes natural substances that have favorable pharmacologic profile and promising biological activity. Company’s is focusing its efforts on the lead asset, Sarconeos, which is a MAS receptor activator and could potentially preserve muscle function in muscle-wasting diseases. Sarconeos is being evaluated in the Phase 2b SARA-INT study in sarcopenia, with a potential readout in 2020. Additionally, Biophytis is planning to initiate MYODA clinical program in DMD in 2020 (subject to regulatory approval). When Sarconeos is successfully out-licensed,Biophytis is planning to pursue the development of its second asset, Macuneos, in the dry form of age-related maculardegeneration (AMD).
Hier ist, und das kommt öfters vor, ein thread ohne Verlinkung zur Aktie.
Ich wollte neulich auch ein Thema erstellen, konnte aber nicht verlinken. Da mich es immer nervt, nicht zur Aktie springen zu können,
hab ich das dann ganz gelassen. Auf mein "talk" Thema antwortet kein Schwein und interessieren tut´s auch niemand.
Hier das bitte dann als Off-topic löschen.
Wenn einer das liest, und weiß wie ich (bei Finanzen.net) ein Thema erstelle UND mit einer Aktie Verknüpfen kann, der darf mir das gerne erklären.
Sorry an die thematisch interessierten für diesen Kommentar.
Ich wollte neulich auch ein Thema erstellen, konnte aber nicht verlinken. Da mich es immer nervt, nicht zur Aktie springen zu können,
hab ich das dann ganz gelassen. Auf mein "talk" Thema antwortet kein Schwein und interessieren tut´s auch niemand.
Hier das bitte dann als Off-topic löschen.
Wenn einer das liest, und weiß wie ich (bei Finanzen.net) ein Thema erstelle UND mit einer Aktie Verknüpfen kann, der darf mir das gerne erklären.
Sorry an die thematisch interessierten für diesen Kommentar.
BRUTALST unterbewertete Bioperle ....Biophytis =Kurs 0,21 --Marktkap €4,2 M -- Phase 2b Studie (Sarkopenie) läuft ,Interimanalyse im1Q erwartet -- Start Phase 1/2 (DMD) in kürze , IND approval diese oder nächste Woche = mehr infos hier...https://www.wallstreet-online.de/diskussion/...pipeline-u-spottbillig
Good News ...
https://www.biophytis.com/wp-content/uploads/2019/...-PR-EN-Final.pdf
Dr SamuelAgus, CMO of Biophytis,said “We are pleased to have theopportunity to present the SARA-OBS preliminary analysisat SCWD. The SARA-OBS studywas designed to characterize a population of sarcopenic patients to be included in the SARA-INT Phase 2bstudy and the preliminary data shows that we are recruiting the right patient population, namely patients with severe sarcopenia that are at a high risk for mobility disability. Based on thesepreliminaryfindings we would expect the SARA-INT trial to show that Sarconeos (BIO101) delivers a larger treatment effect versus placebothan initially anticipated.These dataprovide us with greater confidence that the SARA-INT study will deliver a positive outcome andfurther emphasizesthe potential of Sarconeos (BIO101) as a treatment for neuromuscular diseases.”
https://www.biophytis.com/wp-content/uploads/2019/...-PR-EN-Final.pdf
Dr SamuelAgus, CMO of Biophytis,said “We are pleased to have theopportunity to present the SARA-OBS preliminary analysisat SCWD. The SARA-OBS studywas designed to characterize a population of sarcopenic patients to be included in the SARA-INT Phase 2bstudy and the preliminary data shows that we are recruiting the right patient population, namely patients with severe sarcopenia that are at a high risk for mobility disability. Based on thesepreliminaryfindings we would expect the SARA-INT trial to show that Sarconeos (BIO101) delivers a larger treatment effect versus placebothan initially anticipated.These dataprovide us with greater confidence that the SARA-INT study will deliver a positive outcome andfurther emphasizesthe potential of Sarconeos (BIO101) as a treatment for neuromuscular diseases.”
Nach pullback wieder guter einstiegspunkt ..IND approval für DMD Studie müsste spätestens nächste Woche kommen ..Marktkap bei nur €4,5 Million
Marktkap nur €4 millönchen glaube da gibts nichts günstigeres als dieses Bio-Unternehmen ... Interimsdaten von der Phase 2b Studie gibts nächstes Quartal wenn positive gibts ne Explosion
Angehängte Grafik:
pipieline-biophytis1.jpg (verkleinert auf 47%)
pipieline-biophytis1.jpg (verkleinert auf 47%)
GOOD NEWS heute bei Biophytis....könnte einen netten kleinen jump geben
Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD)
https://www.biophytis.com/wp-content/uploads/2019/...arance-PR-EN.pdf
Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD)
https://www.biophytis.com/wp-content/uploads/2019/...arance-PR-EN.pdf